The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy.
Harris
Todd R
TR
Department of Entomology and Cancer Center, University of California, Davis, CA 95616, USA.
Li
Ning
N
Chiamvimonvat
Nipanvan
N
Hammock
Bruce D
BD
D006332:Cardiomegaly / Q000188:drug therapy*; D004727:Endothelium / Q000187:drug effects; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D004851:Epoxide Hydrolases
Circ Res. 2002 Nov 1;91(9):776-81
12411391
J Biol Chem. 2001 Oct 5;276(40):37621-9
11448959
Cardiovasc Drug Rev. 2006 Summer;24(2):169-88
16961727
Am J Physiol Renal Physiol. 2005 Sep;289(3):F496-503
16093425
Circulation. 2004 Apr 6;109(13):1580-9
15066961
Am J Med Sci. 2003 Jul;326(1):15-24
12861121
J Biol Chem. 1998 Apr 3;273(14):8232-9
9525929
Oncogene. 1999 Nov 22;18(49):6867-74
10602462
Cell. 1996 Oct 4;87(1):13-20
8858144
J Pharmacol Exp Ther. 1995 Aug;274(2):798-804
7636743
Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):42-9
17164131
Circulation. 2004 Mar 16;109(10):1196-205
15023894
Annu Rev Pharmacol Toxicol. 2005;45:311-33
15822179
J Cardiovasc Pharmacol. 2007 Sep;50(3):225-37
17878749
Am J Physiol Cell Physiol. 2007 Mar;292(3):C996-1012
16987999
Science. 2001 Nov 30;294(5548):1871-5
11729303
Biochem Pharmacol. 2004 Apr 15;67(8):1445-57
15041462
Circulation. 2002 Jan 1;105(1):85-92
11772881
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18733-8
17130447
FASEB J. 1992 Jan 6;6(2):731-6
1537463
Heart Fail Rev. 2001 Mar;6(2):129-36
11309531
Circulation. 2002 Jan 29;105(4):509-15
11815436
Nat Immunol. 2002 Mar;3(3):221-7
11875461
Clin Exp Pharmacol Physiol. 2004 Sep;31(9):650-5
15479174
Prog Lipid Res. 2005 Jan;44(1):1-51
15748653
J Mol Cell Cardiol. 2000 Oct;32(10):1767-78
11013121
Circulation. 2003 Aug 12;108(6):638-40
12912791
J Cell Biol. 2002 Dec 23;159(6):1019-28
12486112
Basic Res Cardiol. 2007 Jul;102(4):279-97
17530315